Eyenovia Inc (EYEN)
0.7578
+0.05
(+6.40%)
USD |
NASDAQ |
Apr 30, 16:00
0.7578
0.00 (0.00%)
After-Hours: 20:00
Eyenovia Cash from Financing (TTM): 19.79M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 19.79M |
September 30, 2023 | 22.48M |
June 30, 2023 | 14.58M |
March 31, 2023 | 9.26M |
December 31, 2022 | 21.51M |
September 30, 2022 | 30.49M |
June 30, 2022 | 27.43M |
March 31, 2022 | 35.65M |
December 31, 2021 | 21.46M |
September 30, 2021 | 9.264M |
June 30, 2021 | 24.14M |
March 31, 2021 | 16.80M |
December 31, 2020 | 20.86M |
Date | Value |
---|---|
September 30, 2020 | 20.77M |
June 30, 2020 | 19.04M |
March 31, 2020 | 18.54M |
December 31, 2019 | 13.51M |
September 30, 2019 | 16.33M |
June 30, 2019 | 3.426M |
March 31, 2019 | 3.358M |
December 31, 2018 | 27.62M |
September 30, 2018 | 24.64M |
June 30, 2018 | 31.35M |
March 31, 2018 | 31.35M |
December 31, 2017 | 6.604M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
3.426M
Minimum
Jun 2019
35.65M
Maximum
Mar 2022
19.23M
Average
19.79M
Median
Dec 2023
Cash from Financing (TTM) Benchmarks
NovaBay Pharmaceuticals Inc | 1.91M |
Alpine Immune Sciences Inc | 165.12M |
Lantern Pharma Inc | -0.50M |
Oragenics Inc | 0.2839M |
MAIA Biotechnology Inc | 9.271M |